DHE (Highly Pure)

<strong>DHE (Highly Pure)</strong>_x000D_ <strong>Catalog number:</strong> B2016155_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 5 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 315.41 g/mol_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> −20°C_x000D_ <strong>Keywords:</strong> Dihydroethidium, Hydroethidine, 7-Diamino-10-ethyl-9-phenyl-9,10-dihydrophenanthridine_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Shafqat R, Flores-Montanez Y, Delbono V, Nahas SJ. Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations J Pain Res. 2020 Apr 30;13:859-864._x000D_ 2: Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role Headache. 2006 Nov;46 Suppl 4:S212-20._x000D_ 3: Silberstein SD, Shrewsbury SB, Hoekman J. Dihydroergotamine (DHE) - Then and Now: A Narrative Review Headache. 2020 Jan;60(1):40-57._x000D_ 4: Yazdani M. Concerns in the application of fluorescent probes DCDHF-DA, DHR 123 and DHE to measure reactive oxygen species in vitro Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):578-82._x000D_ 5: Khalife J, Lauritsen CG, Liang J, Shah SO. DHE-Induced Peripheral Arterial Vasospasm in Primary Raynaud Phenomenon: Case Report Neurohospitalist. 2019 Apr;9(2):113-115._x000D_ 6: Masterson CG, Durham PL. DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons Headache. 2010 Oct;50(9):1424-39._x000D_ 7: Lipton RB, Albrecht D, Bermudez M, Hu J, Hussey E, Levy J. A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults Headache. 2024 Mar;64(3):266-275._x000D_ 8: Bérard A, Kori S. Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes Headache. 2012 Jul-Aug;52(7):1085-93._x000D_ 9: Shikowitz MJ, Abramson AL, Freeman K, Steinberg BM, Nouri M. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results Laryngoscope. 1998 Jul;108(7):962-7._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/30659611">10: Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD(®) ) Device, in Healthy Adult Subjects Headache. 2019 Mar;59(3):394-409. </a>_x000D_ _x000D_ <strong>Products Related to DHE (Highly Pure) can be found at</strong> <a href="https://moleculardepot.com/product-category/Chemicals/"> Chemicals</a>